MX367926B - Composicion farmaceutica para liberacion sostenida de lanreotida. - Google Patents
Composicion farmaceutica para liberacion sostenida de lanreotida.Info
- Publication number
- MX367926B MX367926B MX2016000294A MX2016000294A MX367926B MX 367926 B MX367926 B MX 367926B MX 2016000294 A MX2016000294 A MX 2016000294A MX 2016000294 A MX2016000294 A MX 2016000294A MX 367926 B MX367926 B MX 367926B
- Authority
- MX
- Mexico
- Prior art keywords
- lanreotide
- sustained release
- pharmaceutical composition
- months
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Abstract
La presente invención se relaciona con una composición farmacéutica para una liberación sostenida de lanreótida, en particular para una liberación sostenida compatible con tratamientos terapéuticos por al menos 2 meses. Las composiciones farmacéuticas son particularmente útiles para el tratamiento de enfermedades, para las que la lanreótida está indicada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13290156.2A EP2823808A1 (en) | 2013-07-09 | 2013-07-09 | Pharmaceutical composition for a sustained release of lanreotide |
PCT/EP2014/064586 WO2015004125A1 (en) | 2013-07-09 | 2014-07-08 | Pharmaceutical composition for a sustained release of lanreotide |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016000294A MX2016000294A (es) | 2016-04-28 |
MX367926B true MX367926B (es) | 2019-09-12 |
Family
ID=48832841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016000294A MX367926B (es) | 2013-07-09 | 2014-07-08 | Composicion farmaceutica para liberacion sostenida de lanreotida. |
Country Status (20)
Country | Link |
---|---|
US (1) | US10543249B2 (es) |
EP (2) | EP2823808A1 (es) |
JP (2) | JP2016523945A (es) |
KR (1) | KR102232410B1 (es) |
CN (1) | CN105392470A (es) |
AR (1) | AR096854A1 (es) |
AU (1) | AU2014289332B2 (es) |
CA (1) | CA2917098A1 (es) |
DK (1) | DK3035912T3 (es) |
EA (1) | EA034224B1 (es) |
ES (1) | ES2928676T3 (es) |
HU (1) | HUE060497T2 (es) |
IL (1) | IL243027A0 (es) |
MX (1) | MX367926B (es) |
PL (1) | PL3035912T3 (es) |
PT (1) | PT3035912T (es) |
SG (1) | SG11201510698QA (es) |
TW (1) | TWI715520B (es) |
UA (1) | UA116569C2 (es) |
WO (1) | WO2015004125A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109381695A (zh) * | 2017-08-09 | 2019-02-26 | 武汉武药科技有限公司 | 一种门冬氨酸帕瑞肽注射液及其制备方法和用途 |
FR3079421A1 (fr) | 2018-03-28 | 2019-10-04 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
ES2902784T3 (es) | 2019-10-24 | 2022-03-29 | Sun Pharmaceutical Ind Ltd | Una forma de dosificación parenteral estable de acetato de Cetrorelix |
GR1010059B (el) * | 2020-08-10 | 2021-08-13 | Φαρματεν Α.Β.Ε.Ε. | Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων |
US20230277417A1 (en) | 2020-08-07 | 2023-09-07 | Pharmathen S.A. | Process and apparatus for preparing viscous pharmaceutical formulations |
LU101974B1 (en) | 2020-08-07 | 2022-02-07 | Pharmathen Sa | Process and apparatus for preparing viscous pharmaceutical formulations |
WO2023092148A1 (en) * | 2021-11-22 | 2023-05-25 | SpecGx LLC | Injectable sustained release pharmaceutical composition |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US271189A (en) * | 1883-01-23 | beals | ||
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
CN101590011A (zh) * | 1994-09-02 | 2009-12-02 | 科学研究与运用咨询公司 | 肽从药物组合物中的持续释放 |
IL127769A (en) * | 1996-07-03 | 2006-10-31 | Alza Corp | Non-aqueous protic preparations of peptides |
FR2762319A1 (fr) | 1997-04-18 | 1998-10-23 | Pharma Biotech | Microcapsules presentant une liberation prolongee et leur procede de preparation |
FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
IT1318539B1 (it) * | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
CN1415378A (zh) | 2002-10-22 | 2003-05-07 | 南京长澳医药科技有限公司 | 生长抑素冻干粉针及其制备工艺 |
US20040247672A1 (en) | 2003-05-16 | 2004-12-09 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
WO2006075124A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
CN101022822B (zh) * | 2004-08-24 | 2012-06-27 | 第一三共株式会社 | 生理学活性肽的液体制剂 |
WO2006065951A2 (en) * | 2004-12-15 | 2006-06-22 | Qlt Usa, Inc. | Sustained delivery formulations of octreotide compounds |
GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
FI120057B (fi) * | 2007-07-13 | 2009-06-15 | Andritz Oy | Laite ja menetelmä lipeäruiskun puhdistamiseksi ja jäähdyttämiseksi |
CA2710406A1 (en) | 2007-09-11 | 2009-04-09 | Dorian Bevec | Use of a peptide as a therapeutic agent |
US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
WO2009095450A1 (en) * | 2008-01-30 | 2009-08-06 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
ES2600797T3 (es) | 2008-08-12 | 2017-02-10 | Novartis Ag | Composiciones farmacéuticas |
EP2168983A1 (fr) | 2008-09-30 | 2010-03-31 | Ipsen Pharma | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
AU2009336723B2 (en) * | 2008-12-15 | 2013-06-06 | Novartis Ag | Nanoparticle compositions |
US20120172650A1 (en) * | 2009-03-18 | 2012-07-05 | Laurence Katznelson | Use of somatostatin or an analogue thereof in combination with external radiation therapy |
US9352012B2 (en) * | 2010-01-13 | 2016-05-31 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
PE20141297A1 (es) * | 2011-12-05 | 2014-10-09 | Camurus Ab | Formulaciones peptidicas robustas de liberacion controlada |
-
2013
- 2013-07-09 EP EP13290156.2A patent/EP2823808A1/en not_active Ceased
-
2014
- 2014-07-08 CA CA2917098A patent/CA2917098A1/en not_active Abandoned
- 2014-07-08 KR KR1020167003036A patent/KR102232410B1/ko active IP Right Grant
- 2014-07-08 WO PCT/EP2014/064586 patent/WO2015004125A1/en active Application Filing
- 2014-07-08 PL PL14736812.0T patent/PL3035912T3/pl unknown
- 2014-07-08 SG SG11201510698QA patent/SG11201510698QA/en unknown
- 2014-07-08 DK DK14736812.0T patent/DK3035912T3/da active
- 2014-07-08 US US14/903,010 patent/US10543249B2/en active Active
- 2014-07-08 TW TW103123446A patent/TWI715520B/zh active
- 2014-07-08 ES ES14736812T patent/ES2928676T3/es active Active
- 2014-07-08 EA EA201690191A patent/EA034224B1/ru not_active IP Right Cessation
- 2014-07-08 AR ARP140102537A patent/AR096854A1/es not_active Application Discontinuation
- 2014-07-08 HU HUE14736812A patent/HUE060497T2/hu unknown
- 2014-07-08 JP JP2016524794A patent/JP2016523945A/ja active Pending
- 2014-07-08 AU AU2014289332A patent/AU2014289332B2/en active Active
- 2014-07-08 CN CN201480038507.4A patent/CN105392470A/zh active Pending
- 2014-07-08 EP EP14736812.0A patent/EP3035912B1/en active Active
- 2014-07-08 MX MX2016000294A patent/MX367926B/es active IP Right Grant
- 2014-07-08 PT PT147368120T patent/PT3035912T/pt unknown
- 2014-08-07 UA UAA201601113A patent/UA116569C2/uk unknown
-
2015
- 2015-12-21 IL IL243027A patent/IL243027A0/en unknown
-
2019
- 2019-02-25 JP JP2019032085A patent/JP6811270B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US10543249B2 (en) | 2020-01-28 |
JP6811270B2 (ja) | 2021-01-13 |
JP2019073564A (ja) | 2019-05-16 |
CN105392470A (zh) | 2016-03-09 |
IL243027A0 (en) | 2016-02-29 |
EA201690191A1 (ru) | 2016-06-30 |
WO2015004125A1 (en) | 2015-01-15 |
EA034224B1 (ru) | 2020-01-20 |
TW201536346A (zh) | 2015-10-01 |
EP2823808A1 (en) | 2015-01-14 |
EP3035912B1 (en) | 2022-08-31 |
KR20160030232A (ko) | 2016-03-16 |
DK3035912T3 (da) | 2022-10-03 |
EP3035912A1 (en) | 2016-06-29 |
JP2016523945A (ja) | 2016-08-12 |
ES2928676T3 (es) | 2022-11-21 |
HUE060497T2 (hu) | 2023-03-28 |
US20160151447A1 (en) | 2016-06-02 |
MX2016000294A (es) | 2016-04-28 |
CA2917098A1 (en) | 2015-01-15 |
PT3035912T (pt) | 2022-10-26 |
AR096854A1 (es) | 2016-02-03 |
SG11201510698QA (en) | 2016-01-28 |
KR102232410B1 (ko) | 2021-03-29 |
TWI715520B (zh) | 2021-01-11 |
AU2014289332A1 (en) | 2016-02-11 |
UA116569C2 (uk) | 2018-04-10 |
PL3035912T3 (pl) | 2022-12-05 |
AU2014289332B2 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
GB201209613D0 (en) | New compounds | |
GB201118656D0 (en) | New compounds | |
UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
NZ749217A (en) | Androgen receptor modulator and uses thereof | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
MX346224B (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
MX349004B (es) | Nuevos compuestos. | |
NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
EA201690187A1 (ru) | Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |